For removal of DOACs from plasma specimens

Diagnostic laboratories often face problems since the presence of Direct Oral Anticoagulants (DOACs) in human plasma samples interfere with various hemostasis assays. DOAC-Remove™ is intended to be used for the removal of Direct Oral Anticoagulant (DOAC) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban, edoxaban and argatroban:

  • One tablet of DOAC-Remove™ neutralizes the influence of DOACs in 1mL (range 0.5 to 2 mL) citrated plasma sample.
  • DOAC-Remove™ reduces the false positivity for lupus anticoagulants and is useful for eliminating interference on routine coagulation assays such as APTT, PT, TT, single factors, chromogenic assays and APC-R.
  • After incubation and centrifugation, the plasma supernatant can immediately be used for hemostasis assays, or it can be frozen respectively.
  • No significant effect on clotting factors has been reported.
  • DOAC-Remove™ has a 5 year shelf life.
  • DOAC-Remove™ presentations:

Order now! DOAC-Remove 20 – Ref. No. 5D-82410A, 20 tablets – DOAC-Remove 20 Insert for download 

Order now! DOAC-Remove 50 – Ref. 5D-82410B, 50 tablets – DOAC-Remove 50 Insert for download 

Order now! DOAC-Remove 250 – Ref. 5D-82410C, 250 tablets – DOAC-Remove 250 Insert for download